In addition, mutations that are predicted to disrupt phosphorylation and degradation of β-catenin are frequent in hepatocellular carcinoma (HCC)63,64, medulloblastoma65, and ovarian cancer66; whereas deletions and truncation mutations in Axin1 are common in HCC and colorectal tumors67,68 (Table 1). This evidence concerns the gene AXIN1 and hepatocellular carcinoma.